Egret Therapeutics, a clinical-stage biotechnology company developing novel immune-modulatory therapies for secondary inflammation following traumatic and ischemic disorders, recently announced the signing of a non-binding Memorandum of Understanding (MOU) with Genexine to acquire full right, title, and interest in its lead asset, GX-P1 (also known as EGT-101).
“Securing full ownership of EGT-101 is a defining moment for Egret,” said Daniel Chai, MD, Co-Founder and CEO of Egret Therapeutics. “By consolidating the intellectual property for this first-in-class PD-1 agonist, we gain the strategic autonomy needed to accelerate development and maximize the potential of our platform to deliver life-changing therapies to patients suffering from acute secondary inflammation.”
Under the terms of the MoU, signed March 6, 2026, the parties intend to transition Egret’s current exclusive global license into an outright asset transfer. Subject to the execution of a definitive agreement, the proposed transaction would grant Egret sole ownership of the licensed product and all related intellectual property and materials.
“This MoU represents a transformative milestone for Egret,” said Henry Park, Chief Financial Officer of Egret Therapeutics. “Transitioning from licensee to outright owner of EGT-101 significantly strengthens our strategic position, simplifies our intellectual property structure, and provides the flexibility to pursue strategic partnerships and long-term value creation opportunities.”
Vedik Navale, Chief of Staff at Egret Therapeutics, added: “Our preclinical data show that PD-L1 dramatically reduces Malignant Cerebral Edema to preserve neurological function and improve survival. We are focused on executing our Phase 1b/2a study in Malignant Cerebral Edema following Large Vessel Occlusion Stroke with the urgency these patients need.”
About Malignant Cerebral Edema Following Large Vessel Occlusion Stroke (MCE-LVO)
MCE is a life-threatening complication that affects approximately 80,000 LVO patients in the United States. Even after successful reperfusion therapy, most patients remain at risk for catastrophic brain swelling driven by secondary inflammation. Untreated MCE carries an estimated 80% one-week mortality rate and significant loss of neurological function in the patients who survive. Existing treatment options are limited to medical management, which provides only temporary symptom relief, and decompressive hemicraniectomy, an invasive procedure that removes a large part of the skull, which reduces mortality but leaves survivors with severe, permanent disability. No approved pharmacotherapy exists that targets the underlying immune-driven mechanism of cerebral edema. EGT-101 is designed to address this unmet need by intercepting the PD-1+ monocyte-driven inflammatory cascade responsible for fatal cerebral swelling.
To learn more about Biotechnology, click on the links below.
STEMCELL Technologies Successfully Acquires All Assets of SQZ Biotechnologies Company
CRISPR QC launches three Innovative Products and unveils Revamped Website
Harbour BioMed Acquires Common Stock in Spruce Biosciences
